Portolan Capital Management LLC Buys 218,901 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Portolan Capital Management LLC raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 201.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 327,764 shares of the company’s stock after buying an additional 218,901 shares during the period. Amphastar Pharmaceuticals comprises about 1.2% of Portolan Capital Management LLC’s investment portfolio, making the stock its 23rd biggest position. Portolan Capital Management LLC owned 0.68% of Amphastar Pharmaceuticals worth $15,906,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. TD Asset Management Inc increased its holdings in shares of Amphastar Pharmaceuticals by 67.4% in the 2nd quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock worth $67,663,000 after buying an additional 680,976 shares during the last quarter. Epoch Investment Partners Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 35.1% in the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock worth $43,154,000 after buying an additional 280,390 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 19.7% in the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock worth $29,616,000 after buying an additional 121,764 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 84.6% during the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock valued at $29,550,000 after purchasing an additional 338,653 shares during the last quarter. Finally, Boston Trust Walden Corp bought a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at $26,189,000. Institutional investors own 65.09% of the company’s stock.

Insider Transactions at Amphastar Pharmaceuticals

In other news, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the sale, the director now directly owns 75,409 shares in the company, valued at $3,504,256.23. The trade was a 3.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Richard K. Prins sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total transaction of $244,000.00. Following the completion of the sale, the director now owns 31,471 shares of the company’s stock, valued at $1,535,784.80. This represents a 13.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,533 shares of company stock valued at $1,378,252. Company insiders own 27.10% of the company’s stock.

Analyst Upgrades and Downgrades

AMPH has been the topic of several recent research reports. Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Wells Fargo & Company initiated coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 target price on the stock. Finally, StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $60.33.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock opened at $44.92 on Wednesday. The firm has a market cap of $2.16 billion, a PE ratio of 14.97, a price-to-earnings-growth ratio of 0.91 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The company’s fifty day simple moving average is $47.73 and its two-hundred day simple moving average is $44.60.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.